Current Headlines

  1. Celladon Licenses mSCF For Gene Therapy
    7/24/2014
    Clinical stage biotech firm Celladon Corporation announced that it has signed an exclusive, global license from Enterprise Partners Venture Capital for the membrane-bound form of the Stem Cell Factor gene (mSCF) as treatment for cardiac ischemia. The license agreement will allow Celladon to use mSCF in gene therapy applications.
  2. BioMarin And Sara Cannon Research Institute UK Partner In EMBRACA Trial
    7/24/2014
    BioMarin Pharmaceutical and Sarah Cannon Research Institute UK announced that they have partnered to recruit patients in the ongoing Phase III EMBRACA clinical trial of BioMarin’s BMN 673 for the treatment of hereditary breast cancer with a BRCA mutation. The trial was officially initiated in October 2013 when BioMarin dosed the first BMN 673 patient.
  3. ABPI, BIA Release FAQ And Guide To Biosimilars
    7/24/2014
    As biosimilars rise to prominence in the pharmaceutical industry, the Association of the British Pharmaceutical Industry (ABPI) and the Bioindustry Association (BIA) have jointly worked on developing materials on biological drugs including biosimilars. The documents include a guide to the medicines and a collection of frequently asked questions.
  4. Scientists Report Discovery Of Biomarker For HIV Vaccine
    7/23/2014
    Scientists from the University of London, St. George’s, and Bionor Pharma published the results of an exploratory analysis of a Phase II study investigating an HIV vaccine that revealed a possible biomarker for patients receiving the vaccine.
  5. Regulus Receives FDA Orphan Status For Rare Kidney Disease Drug
    7/23/2014

    Biopharmaceutical company Regulus Therapeutics announced that the U.S. Food and Drug Administration (FDA) have issued Orphan Drug designation to its RG-012 for the treatment of rare kidney disease Alport syndrome.

  6. aTyr And Partner Universities Publish Human Protein Discovery
    7/23/2014

    aTyr Pharma and its Hong Kong subsidiary Pangu Biopharma announced the discovery of a new class of human proteins called physiocrines which are believed to have potential therapeutic value in a broad range of diseases.

  7. Teva Acquires Labrys, Expands CNS Portfolio
    7/22/2014
    Teva Pharmaceutical announced that it has successfully completed its acquisition of Labrys Biologics.
  8. Researchers Present Alzheimer’s R&D At AAIC 2014
    7/22/2014

    Researchers from pharmaceutical companies and universities presented their latest data on Alzheimer’s R&D at the Alzheimer’s Association International Conference 2014 (AAIC) that took place last week in Copenhagen, Denmark.

  9. Alkermes Starts Phase I Study Of Potential MS Treatment
    7/22/2014

    Dublin drug manufacturer Alkermes has initiated a phase I clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule intended for the treatment of multiple sclerosis (MS). The launch of this trial could hopefully lead to some good news for those 400,000 individuals in the U.S. and 2.5 million people worldwide affected by MS.

  10. AbbVie Acquires Shire To Reincorporate In U.K.
    7/21/2014
    AbbVie and Shire announced in a cooperation agreement that AbbVie has agreed to acquire Shire in a $54 billion takeover deal. The acquisition of the U.K. pharmaceutical company will allow AbbVie to reincorporate in the U.K. and lower its tax bill from 23 percent in the U.S. to 13 percent in the U.K., according to The New York Times. The deal follows a recent trend of U.S. firms reincorporating in the U.K. to lower taxes, although top executives including AbbVie’s CEO Richard A. Gonzalez, have denied that the primary reason is financial. Rather, he says the Shire acquisition was a strategic fit.
Newsletter Signup
Newsletter Signup